Fortrea (FTRE) Citi Annual Global Healthcare Conference 2025 summary

Market and industry trends

• Sequential improvement in book-to-bill ratio in Q3, attributed to dissipating customer hesitation post-CEO transition and increased commercial execution.

• Biopharma and biotech clients are resuming pipeline activities, with cautious optimism as funding conditions improve but remain below 2018-2019 levels.

• New client acquisition is broad-based, spanning small biotech to large pharma, and RFP volumes are rising above market demand.

• Pipeline strength and commercial momentum are expected to continue into Q4.

• Recent policy clarity and industry announcements have reduced uncertainty, encouraging trial initiations.

Strategic initiatives and operational changes

• Focus on a bespoke biotech operating model, matching staff profiles to client needs and geographies for better project fit.

• Emphasis on project management excellence, de-layering, and empowering teams to make real-time decisions.

• Continuous journey to improve talent, project management, and commercial, operational, and financial excellence, with no fixed endpoint.

• Shift from legacy systems to independent, project-level financial management, enabling better margin control and profitability tracking.

• Right-sizing and cost actions are designed to enhance agility and support growth, with hiring to resume as demand returns.

Financial performance and outlook

• Revenue guidance raised to $2.7–$2.75 billion, driven by increased pass-throughs in phase I and full-service business.

• EBITDA guidance set at $175–$195 million, with cost reductions offsetting headwinds from R&D tax credits and pass-throughs.

• $150 million in gross cost savings targeted for the year, with $90 million net after reinvestment in employees; over 2,000 resources reduced since the spin.

• SG&A as a percent of revenue targeted to decrease to 11–12% over the next 12–18 months, with further efficiency gains expected.

• Cancellations remain within historical norms, with limited exposure to major industry headwinds.